Physician profile
Carmen Herrera
NPI 1720227572
$8,229.39
in general payments reported to CMS, 2019-2025
29 companies · $1,195 in 2025
The $1,195 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,022 · 2020: $576 · 2021: $601 · 2022: $545 · 2023: $755 · 2024: $1,536 · 2025: $1,195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,486.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,486.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,937.86 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,702.93 | 2019-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $1,184.34 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $475.94 | 2019-2025 | Jardiance |
| Amgen INC. | $399.21 | 2019-2025 | Repatha, Repatha, Otezla |
| Pfizer INC. | $376.93 | 2019-2025 | |
| Exact Sciences Corporation | $279.48 | 2023-2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $253.79 | 2024-2025 | Voquezna |
| Amarin Pharma, INC. | $230.78 | 2019-2023 | |
| Abbott Laboratories | $229.96 | 2022-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $176.95 | 2021-2025 | Shingrix, Arexvy, Fluarix Quadrivalent |
| Merck Sharp & Dohme LLC | $129.54 | 2019 | |
| Mylan Specialty L.P. | $125.00 | 2019 | |
| Astellas Pharma US INC | $110.72 | 2019-2023 | Veozah |
| Allergan, INC. | $105.95 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Veran Medical Technologies, INC. | $101.90 | 2019 | |
| Sanofi-Aventis U.S. LLC | $86.69 | 2019-2023 | |
| Biocompatibles, INC. | $48.65 | 2019 | |
| Sumitomo Pharma America, INC. | $45.90 | 2024-2025 | Gemtesa |
| Xeris Pharmaceuticals, INC. | $38.46 | 2025 | Gvoke Hypopen |
| Azurity Pharmaceuticals, INC. | $36.79 | 2024 | Horizant, Edarbi |
| Novartis Pharmaceuticals Corporation | $33.92 | 2022 | |
| Dexcom, INC. | $21.30 | 2025 | Dexcom G6 Transmitter |
| Boston Scientific Corporation | $20.88 | 2019 | |
| Scilex Pharmaceuticals INC. | $19.66 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $14.35 | 2025 | Zoryve |
| Currax Pharmaceuticals LLC | $14.21 | 2025 | Contrave |
| Medtronic USA, INC. | $13.69 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.61 | 2025 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carmen Herrera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.